Please ensure Javascript is enabled for purposes of website accessibility
ORIGINAL PAPER
Analysis of postoperative course after pancreatic resections – experience of one centre
 
More details
Hide details
 
Submission date: 2018-12-15
 
 
Acceptance date: 2018-12-17
 
 
Publication date: 2018-12-31
 
 
Medical Studies 2018;34(4):317-324
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Pancreatic resections belong to the most difficult surgical procedures and are still burdened with a high percentage of complications.

Aim of the research:
To analyse both the medical records of patients qualified for surgical treatment and the postoperative course after procedures of radical resection of the pancreas, with consideration of the most severe complications.

Material and methods:
Postoperative courses were analysed in 100 patients who had undergone pancreatic resection.

Results:
The most frequent indications for pancreatic resection were: cancer of the ampulla of Vater (30), pancreatic cancer (24), inflammatory tumours (16), and benign cystic tumours (12). In 8 cases, pancreatic resection (distal) was an element of the surgery due to advanced gastric cancer, while the remaining were: lymphoma (2), neuroendocrine tumour (2), adenoma with high-grade dysplasia involving the ampulla of Vater (2), GIST (1), IPMN (1), fibromatosis (1), and injury (1). The most frequently performed surgery was partial resection of the organ (73: proximal resection – 35, distal resection – 38). Total pancreatectomy was performed in 20 patients, and in 3 patients the surgery was limited to resection of the tumour. The dominant postoperative complications were pancreatic fistulas (9%) and haemorrhages (5%). Only one case of fistula was surgically treated. Surgical intervention was necessary in all cases of haemorrhagic complications (in 2 patients – several times). During the postoperative period 5 deaths were registered (5%).

Conclusions:
Pancreatic surgery remains a very difficult discipline, which requires not only excellent surgical technique, but also skill in the management of postoperative complications.
REFERENCES (20)
1.
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 2140-1.
 
2.
Peng YC, Lin CL, Hsu WY, Lu IT, Yeh HZ, Chang CS, Kao CH. Proton pump inhibitor use is associated with risk of pancreatic cancer: a nested case-control study. Dose Response 2018; 16: 1559325818803283.
 
3.
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22: 9694-705.
 
4.
Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD; IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology 2016; 16: 14-27.
 
5.
Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-13.
 
6.
Paez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am 2012; 41: 189-209.
 
7.
Muncibi F, Paez DC, Matassi F, Carulli C, Nistri L, Innocenti M. Long term results of percutaneous fixation of proximal humerus fractures. Indian J Orthop 2012; 46: 664-7.
 
8.
Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011; 40: 339-51.
 
9.
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-47.
 
10.
Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012; 51: 14-24.
 
11.
Głuszek S, Kozieł D. Determinacja genetyczna w raku trzustki. Medical Studies 2018; 34: 178-82.
 
12.
Okano K, Suzuki Y. Strategies for early detection of resectable pancreatic cancer. World J Gastroenterol 2014; 20: 11230-40.
 
13.
Gluszek S, Kowalik A, Koziel D, Wawrzycka I, Gluszek- Osuch M, Matykiewicz J. CTRC gene polymorphism may increase pancreatic cancer risk – preliminary study. Pol Przegl Chir 2017; 89: 48-53.
 
14.
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, FernandezCruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2017; 161: 584-91.
 
15.
Shrikhande SV, Sivasanker M, Vollmer CM, Friess H, Besselink MG, Fingerhut A, Yeo CJ, Fernandez-delCastillo C, Dervenis C, Halloran C, Gouma DJ, Radenkovic D, Asbun HJ, Neoptolemos JP, Izbicki JR, Lillemoe KD, Conlon KC, Fernandez-Cruz L, Montorsi M, Bockhorn M, Adham M, Charnley R, Carter R, Hackert T, Hartwig W, Miao Y, Sarr M, Bassi C, Büchler MW; International Study Group of Pancreatic Surgery (ISGPS). Pancreatic anastomosis after pancreatoduodenectomy: a position statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2017; 161: 1221-34.
 
16.
Shigemoto Y, Sone D, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Sato N, Matsuda H. Association of deposition of tau and amyloid-beta proteins with structural connectivity changes in cognitively normal older adults and Alzheimer’s disease spectrum patients. Brain Behav 2018: e01145.
 
17.
Wiltberger G, Krenzien F, Atanasov G, Hau HM, Schmelzle M, Bartels M, Benzing C. Pancreaticoduodenectomy for periampullary cancer: does the tumour entity influence perioperative morbidity and long-term outcome? Acta Chir Belg 2018; 118: 341-7.
 
18.
Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg 1995; 221: 635-45.
 
19.
Sandini M, Honselmann KC, Birnbaum DJ, Gavazzi F, Chirica M, Wellner U, Guilbaud T, Bolm L, Angrisani M, Moutardier V, Cereda M, Girard É, Montorsi M, Keck T, Zerbi A, Gianotti L. Preoperative biliary stenting and major morbidity after pancreatoduodenectomy: does elapsed time matter? The FRAGERITA Study Group. Ann Surg 2018; 268: 808-14.
 
20.
Sandini M, Ruscic KJ, Ferrone CR, Warshaw AL, Qadan M, Eikermann M, Lillemoe KD, Fernandez-Del Castillo C. Intraoperative dexamethasone decreases infectious complications after pancreaticoduodenectomy and is associated with long-term survival in pancreatic cancer. Ann Surg Oncol 2018; 25: 4020-6.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top